Sexual Health
PT-141
Also known as: Bremelanotide, Vyleesi
A melanocortin receptor agonist that acts on brain pathways involved in sexual desire; it is approved in the US only for a narrow use in premenopausal women.
Overview
PT-141 is the research name for bremelanotide, a peptide that activates melanocortin receptors in the brain. Unlike drugs that act on blood flow, it is thought to influence the brain pathways involved in sexual desire and arousal.
What the research has looked at
Two randomized phase 3 trials led to the 2019 US approval for hypoactive sexual desire disorder in premenopausal women. Earlier research looked at its effect in men, and development for that use was affected by blood pressure concerns.
What we do not know
- Approval covers only one condition in one population, so benefits outside it are not established.
- Common side effects in trials included nausea and flushing, and it can cause temporary rises in blood pressure.
- Long-term safety data are limited.
Regulatory context
PT-141 is approved in the US only for the use above. Products sold for other purposes are not approved for them.
Related pages
See also Kisspeptin.
References & further reading
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
Educational reference only. Not medical advice. This page does not recommend or describe human use, dosing or sourcing.